[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@StreetCred2017 @StreetCred2018
@StreetCred2018 posts on X about $ifrx, $amgn, $zura, $abbv the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXX -XX%
- X Month XXXXXX +50%
- X Months XXXXXX -XX%
- X Year XXXXXXXXX +106%
Mentions: X #
- X Week XX -XX%
- X Month XX +31%
- X Months XXX -XX%
- X Year XXX +60%
Followers: XXX #
- X Week XXX no change
- X Month XXX +0.12%
- X Months XXX +12%
- X Year XXX -XXXX%
CreatorRank: undefined #
Social Influence #
Social category influence stocks XXXX% finance XXXX% technology brands XXXX%
Social topic influence $ifrx 3.74%, $amgn 3.74%, $zura 0.93%, $abbv 0.93%, $okra 0.93%, $avtx 0.93%, $snf 0.93%, all the 0.93%, rates 0.93%, approved XXXX%
Top accounts mentioned or mentioned by @quick2smile @o248528307 @3in5saved @maximusholla @dogtor01416800 @rdd147 @kobeissiletter @biovalues @peterschiff @billackman @seedy19tron @realdonaldtrump @elonmusk @semodough @zerohedge @lawdawg050 @nawachisrheum @realalexjones @legitinvest @ankitsh85153215
Top assets mentioned Amgen, Inc. (AMGN) AbbVie Inc (ABBV) Hundred Million (100M)
Top Social Posts #
Top posts by engagements in the last XX hours
"@LegitInvest @BioValues They never liked Moonlake but have great analysis on all the other HS players in report. $ZURA $IFRX $ABBV $OKRA $AVTX $SNF Seemingly liking Inflarx over others due to value / unique mechanism and it always beat out avacopan - now owned by $AMGN"
X Link @StreetCred2017 2025-10-03T14:12Z XXX followers, XXX engagements
"@Quick2smile @ANKITSH85153215 Interesting and I think Inflarx did same thing w cSCC At end of the day it (C5a antagonist) may wind up being used in combination w some chemo agent. $AMGN $IFRX #PancreaticCancer needs anything that improves XX% survival rates. Compassionate use"
X Link @StreetCred2017 2025-10-06T12:50Z XXX followers, XXX engagements
"@ANKITSH85153215 Friday study showing $AMGN c5aR pathway complement system and soc chemo reduced pancreatic cancer tumor 80%. Big for Avacopan already FDA approved AAV. $IFRX best in c5aR class. #PancreaticCancer very low X yr survival 12%"
X Link @StreetCred2017 2025-10-06T11:09Z XXX followers, XXX engagements
"@Investorclimber @Biotech_AI Gents - any best guess on upside with only X of X showing promise VS both CSU Yes HS -No: or visa versa Guggenheim called 5-10x but seems overly optimistic given need to finance P2b but both wld show pipeline potential. Also partner needed"
X Link @StreetCred2017 2025-10-15T11:40Z XXX followers, XX engagements
"$AMGN Breaking: Avacopan seen blocking pancreatic cancer tumors over XX% when combined with gemcitabine/nab-paclitaxel (standard PDAC chemo) XX% Avacopan motherly only - looks like way bigger market for C5aR inhibitor market than just AAV supporting $4b buyout $CCXI $IFRX still at a whopping $100m In vivo CCX168 monotherapy reduced tumor volume by XX% (p0.01); combining it with gemcitabine/nab-paclitaxel (standard PDAC chemo) and immune checkpoint inhibitors (pembrolizumab/ipilimumab) achieved the strongest effectsup to XX% tumor reduction increased CD8+ T-cell infiltration (p0.01) and"
X Link @StreetCred2017 2025-10-05T23:47Z XXX followers, XXX engagements